What is SXTP stock price today?

SXTP (60 Degrees Pharmaceuticals Inc) stock is trading at $1.73 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is SXTP stock going up or down today?

SXTP stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy SXTP stock now?

The decision to buy SXTP depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is SXTP a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for SXTP based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is SXTP stock overvalued or undervalued?

Use our DCF valuation calculator to determine if SXTP is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is SXTP's P/E ratio?

P/E ratio data for SXTP will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is SXTP's market cap?

SXTP (60 Degrees Pharmaceuticals Inc) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is SXTP's price to book ratio?

Price-to-book ratio for SXTP is available on our dashboard along with other valuation metrics.

Does SXTP pay dividends?

SXTP does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is SXTP's dividend yield?

SXTP does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is SXTP stock a good long-term investment?

SXTP's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is SXTP's revenue growth rate?

SXTP has shown revenue growth of 0.2% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for SXTP are available on our dashboard with complete income statement analysis.

What are the risks of investing in SXTP?

Key risks for SXTP include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does SXTP compare to its competitors?

Compare SXTP to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize SXTP's performance and positioning.

What is SXTP's stock price target for 2026?

Our AI model provides price targets for SXTP based on fundamental analysis: Bull case $2.25 (+30%), Base case $1.99 (+15%), Bear case $1.56 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about SXTP?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for SXTP. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is SXTP's next earnings report?

SXTP reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

SXTP - 60 Degrees Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$1.73

$-0.23 (-11.73%)

About 60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.

SXTP Key Statistics

Market Cap

$5.17M

EPS

$-11.73

Revenue Growth

+0.2%

Employees

How SXTP Compares to Peers

SXTP has the fastest revenue growth among competitors

SXTP is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
SXTP(This stock)	$5.17M	N/A	0%	0.0%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

60 Degrees Pharmaceuticals Inc Company Information

Headquarters: District Of Columbia; U.S.A
Website: www.60degreespharma.com
Sector: Health Care
Industry: Biotechnology

About 60 Degrees Pharmaceuticals Inc

SXTP Key Statistics

How SXTP Compares to Peers

60 Degrees Pharmaceuticals Inc Company Information

Upcoming Events for SXTP